Copyright
©The Author(s) 2017.
World J Gastrointest Pharmacol Ther. Feb 6, 2017; 8(1): 67-73
Published online Feb 6, 2017. doi: 10.4292/wjgpt.v8.i1.67
Published online Feb 6, 2017. doi: 10.4292/wjgpt.v8.i1.67
Table 1 Respondents’ demographics, self-reported expertise and scope of inflammatory bowel disease practice
Frequency | Percentage | ||
Sex | Male | 46 | 47% |
Female | 52 | 53% | |
Age, yr | 20-29 | 7 | 7% |
30-44 | 45 | 46% | |
45-60 | 40 | 41% | |
> 60 | 6 | 6% | |
Years in practice, yr | < 5 | 11 | 11% |
5-9 | 21 | 22% | |
10-14 | 17 | 17% | |
15-19 | 10 | 10% | |
≥ 20 | 39 | 40% | |
Profession | Gastroenterology trainee | 17 | 17% |
Gastroenterology consultant | 51 | 52% | |
IBD nurse specialist | 28 | 29% | |
Other | 2 | 2% | |
Geographic region | England | 92 | 95% |
Scotland | 2 | 2% | |
Wales | 2 | 2% | |
Northern Ireland | 1 | 1% | |
Self-rated level of IBD interest in medically qualified staff | General gastroenterologist | 32 | 46% |
Interest in IBD | 18 | 27% | |
Expert IBD physician | 18 | 27% | |
IBD patients per week | Range 0-150 | ||
Mean 25 |
Table 2 Estimation of non-adherence levels by respondents and percentage in line with evidence
Medication | Column A: literature-based non-adherence levels | Column B: perceived mean non-adherence levels | Proportion who estimated non-adherence levels below the levels in column A |
Mesalazine | 30%-45% | 20% | 31% |
Immunomodulator therapy | 15%-20% | 10% | 28% |
Biological agents | 5%-10% | 1% | 23% |
Table 3 Association between perception of non-adherence as a frequent problem and reporting non-adherence levels in line with the evidence base
Medication | χ2 value | Degrees of freedom | P value |
Mesalazine | 33.226 | 1 | 0.000 |
Immunomodulator therapy | 12.592 | 2 | 0.002 |
Biological agents | 7.459 | 1 | 0.006 |
Table 4 Association between level of interest in inflammatory bowel disease and estimation of non-adherence to biological therapy
Pearsonχ2 test | What percentage of your patients on biological therapy are non-adherent? | |
Level of interest in IBD for medical staff | χ2 value | 8.863 |
Degrees of freedom | 2.000 | |
P value | 0.012 |
Table 5 Perception of reasons for non-adherence
Rank | Actual side effects of medication | Patient forgets to take medication | Benefits of medication not immediately apparent | Anxiety or depression | Poor patient knowledge of disease | Frequency of dosing | Beliefs about necessity of medication | Concerns over potential side effects |
Ranked 1st | 14.60% | 32.30% | 13.70% | 5.30% | 7.30% | 9.60% | 12.40% | 11.30% |
Ranked 2nd | 9.40% | 25% | 20% | 7.40% | 11.50% | 18.10% | 23.70% | 14.40% |
Ranked 3rd | 7.30% | 11.50% | 18.90% | 8.40% | 8.30% | 21.30% | 20.60% | 23.70% |
Ranked 4th | 14.60% | 7.30% | 11.60% | 7.40% | 18.80% | 11.70% | 15.50% | 12.40% |
Ranked 5th | 10.40% | 12.50% | 16.80% | 13.70% | 14.60% | 9.60% | 10.30% | 16.50% |
Ranked 6th | 24% | 3.10% | 9.50% | 16.80% | 18.80% | 13.80% | 8.20% | 9.30% |
Ranked 7th | 10.40% | 4.20% | 5.30% | 16.80% | 14.60% | 8.50% | 3.10% | 9.30% |
Ranked 8th | 9.40% | 4.20% | 4.20% | 24.20% | 6.30% | 7.40% | 6.20% | 3.10% |
Ranked in top 3 by n = | 30 | 66 | 50 | 20 | 26 | 46 | 55 | 48 |
Overall rank | 6 | 1 | 3 | 8 | 7 | 5 | 2 | 4 |
- Citation: Soobraty A, Boughdady S, Selinger CP. Current practice and clinicians’ perception of medication non-adherence in patients with inflammatory bowel disease: A survey of 98 clinicians. World J Gastrointest Pharmacol Ther 2017; 8(1): 67-73
- URL: https://www.wjgnet.com/2150-5349/full/v8/i1/67.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v8.i1.67